

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 January 2025 (09.01.2025)



(10) International Publication Number
WO 2025/008402 A1

(51) International Patent Classification:

C07D 487/18 (2006.01) A61K 31/5517 (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:

PCT/EP2024/068730

(22) International Filing Date:

03 July 2024 (03.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23183371.6 04 July 2023 (04.07.2023) EP

(71) Applicants: **SANOFI** [FR/FR]; 46 avenue de la Grande Armée, 75017 Paris (FR). **UCB BIOPHARMA SRL** [BE/BE]; Allée de la Recherche 60, 1070 Brussels (BE).

(72) Inventors: **GRECIET, Hélène**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **MONNIER, Olivier**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **ZIRI, Isabelle**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **FLASZ, Jakub Tadeusz**; c/o IPD, UCB, 208 Bath Road, Slough, Berkshire SL1 3WE (GB). **GRAFFEO, Sabrina Raymonde Sophie**; c/o IPD, UCB Biopharma SRL, Allée de la Recherche 60, 1070 Brussels (BE). **ROUGEOT, Céline**; c/o IPD, UCB Biopharma SRL, Allée de la Recherche 60, 1070 Brussels (BE).

(74) Agent: **J A KEMP LLP**; 80 Turnmill Street, London EC1M 5QU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: CRYSTALLINE FORM



(I)

(57) Abstract: Provided herein is a crystalline form of a compound of Formula (I): *i.e.* (7R,14R)-11-[2-(1-aminocyclobutyl)pyrimidin-5-yl]-1-(difluoromethoxy)-6-methyl-6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one. A pharmaceutical composition comprising the crystalline form, and medical uses of the crystalline form and pharmaceutical composition are also described.

WO 2025/008402 A1